Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

High fidelity

How Wave's nucleic acid technology could confer an advantage in Huntington's

February 15, 2016 8:00 AM UTC

Wave Life Sciences Ltd. has set its sights on rare neuromuscular and CNS diseases where its stereopure nucleic acid technology could confer safety and efficacy advantages over competing programs.

Wave was formed in 2012 from the merger of Ontorii Inc. and Chiralgen Ltd. Since 2009 the predecessor companies had been optimizing technologies to design and manufacture stereopure nucleic acids...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article